Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large increase in short interest in March. As of March 13th, there was short interest totaling 26,405 shares, an increase of 102.6% from the February 26th total of 13,032 shares. Based on an average daily trading volume, of 79,912 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Revelation Biosciences in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Revelation Biosciences

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC bought a new stake in Revelation Biosciences during the 4th quarter valued at about $27,000. Armistice Capital LLC purchased a new stake in shares of Revelation Biosciences during the third quarter valued at approximately $114,000. Finally, Sabby Management LLC increased its position in shares of Revelation Biosciences by 214.7% during the third quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock valued at $294,000 after acquiring an additional 141,262 shares in the last quarter. Institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Stock Performance

Shares of Revelation Biosciences stock traded up $0.01 during midday trading on Friday, hitting $1.14. The company had a trading volume of 13,818 shares, compared to its average volume of 678,745. Revelation Biosciences has a 52-week low of $1.11 and a 52-week high of $44.77. The stock has a market capitalization of $4.25 million, a P/E ratio of -0.02 and a beta of -0.10. The company has a 50 day moving average of $1.68 and a 200 day moving average of $3.67.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.24). Equities research analysts forecast that Revelation Biosciences will post -49.33 EPS for the current year.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.